Doxopeg 2 mg Liposomal infusion.
PDF Leaflet Revision Date: 7 August 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Indicated for metastatic breast cancer, advanced ovarian cancer, multiple myeloma, and AIDS-related Kaposi sarcoma.
Dosage (summary)
50 mg/mu00b2 IV every 4 weeks for breast/ovarian cancer; 30 mg/mu00b2 IV on day 4 of bortezomib regimen for multiple myeloma; 20 mg/mu00b2 IV every 2-3 weeks for AIDS-KS.
Special Populations
- Hepatic impairment
- Renal impairment
- Elderly patients
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation; teratogenic effects noted.
Key Drug Interactions
- May potentiate toxicity of other anti-cancer therapies
- Caution with myelotoxic agents
Contraindications
- Hypersensitivity to doxorubicin
- Pregnancy and lactation
- Patients under 18 years
Common side effects
- Neutropenia
- Nausea
- Fatigue
- Stomatitis
- Palmar-plantar erythrodysaesthesia
Counselling Points
- Monitor for infusion reactions
- Avoid pregnancy during treatment
- Report any severe side effects immediately
Serious warnings
- Cardiotoxicity risk
- Myelosuppression
- Infusion reactions
Important Disclaimer
The Doxopeg 2 mg Liposomal infusion. professional information leaflet below is the property of Key Oncologics and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
